Adlai Nortye (FRA:N2U0) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:N2U0 Adlai Nortye Ltd FRA:N2U0
9 GF Score
Price €9.10
! 7 Warning Signs
View Full Analysis

What is Adlai Nortye Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:N2U0 vs OMER, PRME, DNA: Short Interest Comparison

For the Biotechnology subindustry, Adlai Nortye's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Short Interest distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Short Interest falls into.


FRA:N2U0
9GF Score
Adlai Nortye Ltd FRA:N2U0
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adlai Nortye Business Description

Other Exchanges ANL:USA
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
9GF Score

Get the complete analysis for FRA:N2U0

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.10
Price